Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT) - CAM 70129

Description
Percutaneous electrical nerve stimulation (PENS) and percutaneous neuromodulation therapy (PNT) combine the features of electroacupuncture and transcutaneous electrical nerve stimulation. PENS is performed with needle electrodes while PNT uses very fine needle-like electrode arrays placed in close proximity to the painful area to stimulate peripheral sensory nerves in the soft tissue.

For individuals who have chronic pain conditions (e.g., back, neck, neuropathy, headache, hyperalgesia, knee osteoarthritis) who receive PENS, the evidence includes primarily small controlled trials. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. In the highest quality trial of PENS conducted to date, no difference in outcomes was found between the active (30 minutes of stimulation with 10 needles) and the sham (5 minutes of stimulation with 2 needles) treatments. Smaller trials, which have reported positive results, are limited by unclear blinding and short-term follow-up. The evidence is insufficient to determine the effects of the technology on health outcomes. 

For individuals who have chronic pain conditions (e.g., back, neck, neuropathy, headache, hyperalgesia, knee osteoarthritis) who receive PNT, the evidence consists of 1 randomized controlled trial. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. The single trial is limited by lack of investigator blinding, unclear participant blinding, and short-term follow-up. The evidence is insufficient to determine the effects of the technology on health outcomes.  

Background 
CHRONIC PAIN
A variety of chronic musculoskeletal or neuropathic pain conditions, including low back pain, neck pain, diabetic neuropathy, chronic headache, and surface hyperalgesia, presents a substantial burden to patients, adversely affecting function and quality of life.

Treatment
These chronic pain conditions have typically failed other treatments, and percutaneous electrical nerve stimulation (PENS) and percutaneous neuromodulation therapy (PNT) have been evaluated as treatments to relieve unremitting pain.

PENS is similar in concept to transcutaneous electrical nerve stimulation (see evidence review 1.01.09) but differs in that needles are inserted either around or immediately adjacent to the nerves serving the painful area and are then stimulated. PENS is generally reserved for patients who fail to get pain relief from transcutaneous electrical nerve stimulation. PENS is also distinguished from acupuncture with electrical stimulation. In electrical acupuncture, needles are also inserted just below the skin, but the placement of needles is based on specific theories regarding energy flow throughout the human body. In PENS, the location of stimulation is determined by proximity to the pain.

PNT is a variant of PENS in which fine filament electrode arrays are placed near the area causing pain. Some use the terms PENS and PNT interchangeably. It is proposed that PNT inhibits pain transmission by creating an electrical field that hyperpolarizes C fibers, thus preventing action potential propagation along the pain pathway.   

Regulatory Status
In 2002, the Percutaneous Neuromodulation Therapy™ (Vertis Neuroscience) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. The labeled indication is: "Percutaneous neuromodulation therapy (PNT) is indicated for the symptomatic relief and management of chronic or intractable pain and/or as an adjunctive treatment in the management of post-surgical pain and post-trauma pain." In 2006, the Deepwave® Percutaneous Neuromodulation Pain Therapy System (Biowave) was cleared for marketing by FDA through the 510(k) process. FDA determined that this device was substantially equivalent to the Vertis neuromodulation system and a Biowave neuromodulation therapy unit. The Deepwave® system includes a sterile single-use percutaneous electrode array that contains 1014 microneedles in a 1.5-inch diameter area. The needles are 736 μm (0.736 mm) in length; the patch is reported to feel like sandpaper or Velcro. FDA product code: NHI. 

Related Policies
10109 Transcutaneous Electrical Nerve Stimulation
10124 Interferential Current Stimulation
20121 Temporomandibular Joint Dysfunction
701139 Peripheral Subcutaneous Field Stimulation
80158 Cranial Electrotherapy Stimulation (CES) and Auricular Electrostimulation

Policy
Percutaneous electrical neurostimulation or percutaneous neuromodulation therapy is investigational and/ or unproven and therefore considered NOT MEDICALLY NECESSARY. 

Policy Guidelines
The correct CPT code to use for percutaneous electrical nerve stimulation (PENS) and percutaneous neuromodulation therapy (PNT) is the unlisted CPT code 64999. CPT codes for percutaneous implantation of neurostimulator electrodes (i.e., 64553 – 64565) are not appropriate, because PENS and PNT use percutaneously inserted needles and wires rather than percutaneously implanted electrodes. The stimulation devices used in PENS and PNT are not implanted, so CPT code 64590 is also not appropriate.

Benefit Application
BlueCard/National Account Issues
State or federal mandates (e.g., FEP) may dictate that all devices approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational. Therefore, FDA-approved devices may only be assessed on the basis of their medical necessity.

Rationale
Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Percutaneous Electrical Nerve Stimulation
Clinical Context and Therapy Purpose

The purpose of percutaneous electrical nerve stimulation (PENS) in patients who have pain is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does PENS improve the net health outcome in patients with chronic musculoskeletal or neuropathic pain conditions?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is patients with chronic musculoskeletal or neuropathic pain conditions including low back pain, neck pain, diabetic neuropathy, chronic headache, and surface hyperalgesia.

Interventions
The therapy being considered is PENS.

Comparators
The following practice is currently being used: continued medical management of chronic musculoskeletal or neuropathic pain conditions.

Outcomes
Specific outcomes of interest for patients with chronic pain are listed in Table 1. The potential beneficial outcomes of primary interest would be improvements in pain, functioning, and quality of life.

Table 1. Outcomes of Interest for Individuals With Chronic Pain

Outcomes Details
Morbid events Opioid addiction, adverse events
Health status measures Pain relief, functional status
Medication use Number of unsuccessful medication trials, amount of medications needed, dose of medication, dose frequency

The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommends that chronic pain trials should consider assessing outcomes representing 6 core domains: pain, physical functioning, emotional functioning, participant ratings of improvement and satisfaction with treatment, symptoms and adverse events, and participant disposition.2 Table 2 summarizes provisional benchmarks for interpreting changes in chronic pain clinical trial outcome measures per IMMPACT.3

Table 2. Benchmarks for Interpreting Changes in Chronic Pain Outcome Measures

Outcome Domain and Measure Type of Improvement Change
Pain intensity
0 to 10 numeric rating scale
Minimally important
Moderately important
Substantial
10 to 20% decrease
≥ 30% decrease
≥ 50% decrease
Physical functioning
Multidimensional Pain Inventory Interference Scale
Brief Pain Inventory Interference Scale
Clinically important
Minimally important
≥ 0.6 point decrease
1 point decrease
Emotional functioning
Beck Depression Inventory

Profile of Mood States
Total Mood Disturbance
Specific Subscales
Clinically important


Clinically important
Clinically important
≥ 5 point decrease


≥ 10 to 15 point decrease
≥ 2 to 12 point change
Global Rating of Improvement
Patient Global Impression of Change
Minimally important
Moderately important
Substantial
Minimally improved
Much improved
Very much improved

Regarding optimal timing of outcome assessment, this varies with pain setting.4 Per IMMPACT, recommended assessment timing includes at 3, 6, and 12 months in patients with chronic low back pain, 3 to 4 months after rash onset in postherpetic neuralgia, 3 and 6 months in patients with painful chemotherapy-induced peripheral neuropathy, and at various timepoints in the chronic post-surgical pain setting (i.e., 24 to 48 hours after surgery; 3, 6, and 12 months; or surgery-specific times based on the natural history of acute to chronic pain transition).

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

  • To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
  • In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
  • To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
  • Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Musculoskeletal Pain
Systematic Reviews

Plaza-Manzano et al. (2020) evaluated the effects of PENS alone or as an adjunct to other interventions on pain and related disability in adults with musculoskeletal pain conditions.5 This systematic review and meta-analysis included a total of 19 RCTs (Table 3). Overall, the results revealed poor quality of evidence (dependent upon the presence of study limitations, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision of results, and high probability of publication bias), suggesting that PENS alone is associated with a large effect compared with sham and a moderate effect when compared with other interventions for decreasing pain intensity in the short term. Additionally, the combination of PENS with other interventions had a similar poor quality of evidence for a moderate effect for reducing pain intensity than comparative intervention alone. No clear effects of PENS, either alone or in combination, on related disability were seen. None of the included trials were able to blind therapists. Ten of the trials rated a high risk of bias in the item of allocation concealment and 17 in the item of blinding of participants. Beyond these 2 items, the risk of bias in the included trials was low. Of note, the quality of included evidence was negatively impacted by the presence of heterogeneity in the data and an insufficient number of participants to meet the desired significance and power in some RCTs.

Beltran-Alacreu et al. (2022) evaluated the effectiveness of PENS compared to transcutaneous electrical nerve stimulation (TENS) on the reduction of musculoskeletal pain.6 This systematic review and meta-analysis included a total of 9 RCTs in the qualitative analysis, with 7 in the quantitative analysis (N = 527; Table 3). Overall, there was low-quality evidence for increased pain intensity reduction with PENS over TENS, but the difference found was not deemed to be clinically significant. When only studies with low risk of bias were meta-analyzed, there was a moderate quality of evidence that there is no difference between TENS and PENS for pain intensity. Six out of the 9 studies presented high risk for the blinding of participants, and 7 out of 9 were high risk for blinding of personnel. Beyond these 2 items, the risk of bias in the included trials was either low or unclear. Protocols and parameters for the application of PENS and TENS were heterogenous across all trials. The characteristics and results of both systematic reviews are presented in Tables 4 and 5, respectively.

Table 3. Randomized Controlled Trials Included in the Systematic Review/Meta-Analysis

Study

Plaza-Manzano et al. (2020)5

Beltran-Alacreu et al. (2022)6

Ghoname et al. (1999)7
Ghoname et al. (1999)8
Hamza et al. (1999)9  
Weiner et al. (2003)10  
Topuz et al. (2004)11
Yokoyama et al. (2004)12
Weiner et al. (2008)13  
Perez-Palomares et al. (2010)14  
Weiner et al. (2007)15  
Weiner et al. (2013)16  
Da Graca Tarrago et al. (2016)17  
Elbadawy et al. (2017)18  
Dunning et al. (2018)19  
Da Graca Tarrago et al. (2019)20  
Leon-Hernandez et al. (2016)21  
Sumen et al. (2015)22  
Medeiros et al. (2016)23  
Botelho et al. (2018)24  
Dunning et al. (2018)25  
Yoshimizu et al. (2012)26  
Ng et al. (2003)27  
Tsukayama et al. (2002)28  
Cheng et al. (1987)29  
Lehmann et al. (1986)30  

Table 4. Characteristics of the Systematic Review/Meta-Analysis

Study Dates Trials Participants N (Range) Design Duration
Plaza-Manzano et al. (2020)5 1999 – 2019 19 Studies that included adults with musculoskeletal pain receiving any type of PENS intervention compared to an acceptable comparator (sham, placebo, control, or another active intervention) 1617 (24 – 242) RCT Intervention duration (sessions/week) varied significantly among the included trials
Beltran-Alacreu et al. (2022)6 1986 – 2012 9 Studies that compared TENS vs PENS in adults with musculoskeletal pain 527 (20 – 131) RCT Intervention duration range, 2 weeks to 6 months; follow-up range, 1 week to 8 months

PENS: percutaneous electrical nerve stimulation; RCT: randomized controlled trial; TENS: transcutaneous electrical nerve stimulation.

Table 5. Results of the Systematic Review/Meta-Analysis

Study Pain intensity (short-term) Pain intensity (mid-term) Related disability (short-term) Related disability (mid-term)
Plaza-Manzano et al. (2020)5 PENS alone vs sham PENS alone vs other intervention PENS + other intervention vs same intervention alone PENS alone or in combination vs comparative group PENS alone or in combination vs comparative group PENS alone or in combination vs comparative group
N 616 371 730 988 738 568
SMD (95% CI) -1.22 (-1.66 to -0.79) -0.71 (-1.23 to -0.19) -0.70 (-1.02 to -0.37) -0.68 (-1.10 to -0.27) -0.33 (-0.61 to -0.06) -0.21 (-0.52 to 0.10)
I2 (p) 82% (< .001) 80% (.008) 75% (< .001) 89% (.001) 69% (.02) 71% (.19)
  Pain intensity (post-treatment) Pain intensity (follow-up 1 to 8 weeks) Overall pain intensity
Beltran-Alacreu et al. (2022)6 PENS vs TENS PENS vs TENS (Low risk of bias only) PENS vs TENS PENS vs TENS (Low risk of bias only) PENS vs TENS PENS vs TENS (Low risk of bias only)
N 405 55 122 8 527 63
MD (95% CI) -1.21 (-1.92 to -0.5) -0.82 (-1.77 to 0.13) -0.57 (-1.06 to -0.08) -0.80 (-2.60 to 1.0) -1.0 (-1.55 to -0.45) -0.81 (-1.6 to 0.02)
p-value .0008 .09 .02 .38 .0004 .06
I2 (p) 80% (< .0001) 0% (.68) 0% (.72) NA 76% (< .00001) 0% (.86)

CI: confidence interval; MD: mean difference; NA: not applicable; PENS: percutaneous electrical nerve stimulation; SMD: standardized mean difference; TENS: transcutaneous electrical nerve stimulation.

Subsection Summary: Musculoskeletal Pain
Two systematic reviews have not revealed consistent benefit from PENS in musculoskeletal pain disorders. One review (19 RCTs, N = 1617) concluded that PENS could decrease pain intensity but not related disability, while the other (9 RCTs, N = 527) found no significant differences between PENS and TENS in mitigation of pain. These conclusions are uncertain due to important methodological limitations in individual trials included in these reviews, such as high heterogeneity with regard to application methods. Further well-designed RCTs evaluating the effects of PENS alone or in combination with other interventions is needed, particularly with longer term follow-up.

Chronic Low Back Pain
Randomized Controlled Trials

Weiner et al. (2008) reported on an RCT with 200 older adults, which was funded by the National Institutes of Health.13 Subjects with chronic low back pain were randomized to PENS or sham-control treatment, with or without physical conditioning/aerobic exercise, twice a week for 6 weeks. Thus, the 4 treatment groups were PENS alone, sham PENS alone, PENS plus physical conditioning, or sham PENS plus physical conditioning. The sham-control condition consisted of 10 acupuncture needles in identical locations, depth, and duration (30 minutes) as the PENS needles, with a brief (5-minute) stimulation from 2 additional needles. Primary and secondary outcome measures were collected at baseline, 1 week, and 6 months after treatment by a research associate unaware of the treatment. There were no significant adverse events and no differences between the PENS and sham PENS groups in any outcome measure at 1-week or 6-month follow-up. All 4 groups reported reduced pain of a similar level (improvement ranging from 2.3 to 4.1 on the McGill Pain Questionnaire), reduced disability (range, 2.1 to 3.0, on the Roland-Morris Disability Questionnaire), and improved gait velocity (0.04 to 0.07 m/s) that was maintained for 6 months. Although trialists concluded that minimal electrical stimulation (5 minutes with 2 needles) was as effective as usual PENS (30 minutes of stimulation with 10 needles), the lack of benefit of this treatment over the sham-control did not support the use of PENS in patients with chronic low back pain.

An earlier study by Weiner et al. (2003) focused on chronic low back pain in 34 community-dwelling older adults.10 Patients were randomized to twice weekly PENS or sham PENS for 6 weeks. At 3-month follow-up, the treatment group reported a significant reduction in pain intensity and disability, while the control group did not. Yokoyama et al. (2004) used an active control of TENS in a study with 53 patients.12 They reported that patients randomized to PENS twice weekly for 8 weeks (n = 18) had significantly decreased pain levels, physical impairment, and nonsteroidal anti-inflammatory drug use, which continued 1 month after treatment completion compared with a second group that received PENS for 4 weeks followed by TENS for 4 weeks (n = 17), and a third group that received only TENS for 8 weeks (n = 18). While PENS for 8 weeks seemed to demonstrate greater effectiveness in controlling pain for up to 1 month after treatment compared with the other treatment groups, the beneficial effects were not found at the 2-month follow-up.

Several studies were reported by a single academic research group. One of the reports, by Ghoname et al. (1999), compared sham PENS, active PENS, and TENS in 64 patients.31 Active PENS achieved better outcomes than sham PENS on visual analog scale (VAS) pain scores and daily oral analgesic requirements, and it was better than sham PENS and TENS on physical activity, quality of sleep, and preference. Another report by Ghoname et al. (1999) compared sham PENS, active PENS, TENS, and exercise therapy in 60 patients.7 Active PENS resulted in better outcomes than all other modalities regarding VAS pain, reduction in analgesic requirements, physical activity, quality of sleep, and preference. Hamza et al. (1999) varied the duration of active electrical stimulation at 3 levels (15, 30, or 45 minutes) and compared them with sham stimulation in 75 patients.9 These investigators confirmed that sham PENS had the least effect, and results were best when the stimulation lasted 30 or 45 minutes. Ghoname et al. (1999) varied the frequency of the active electrical stimulus, also comparing it with sham stimulation, in 68 patients.8 One level involved active stimulation with alternating 15-Hz and 30-Hz frequencies, while the other active levels had frequencies of 4 Hz and 100 Hz. The alternating frequency technique had the best results, superior to sham PENS.

Subsection Summary: Chronic Low Back Pain
The largest double-blinded, sham-controlled trial on PENS for chronic low back pain found no difference between the active (30 minutes with 10 needles) and sham PENS (5 minutes with 2 needles) at 1 week or 6 months after treatment. While other smaller studies have suggested that active PENS has effects that exceed placebo PENS in the short term, the trialists did not address long-term improvements in pain and functional outcomes, the objective of treating chronic low back pain. No studies on PENS for low back pain have been identified in the last decade.

Chronic Neck Pain
Randomized Controlled Trials

One study by White et al. (2000) compared 2 locations of active stimulation with sham stimulation in 68 patients.32 Local stimulation involved needle insertion at the neck, while remote stimulation entailed needles placed in the lower back. The sham condition received needles with no electrical stimulation at the neck. Outcomes were assessed immediately after completion of a 3-week treatment period. The local placement of active needles resulted in better pain relief, physical activity, quality of sleep, and analgesic use than the local sham treatment or remote active treatment. The study was described as investigator-blinded. Withdrawals were not noted and no long-term outcome data were presented.

Subsection Summary: Chronic Neck Pain
This single study with short-term follow-up does not permit conclusions on the effectiveness of PENS for treating chronic neck pain.

Diabetic Neuropathy
Randomized Controlled Trials

In a crossover study by Hamza et al. (2000), 50 patients with diabetic neuropathic pain for at least 6 months were randomized to sham PENS or active PENS in a 7-week study.33 Racial and ethnic demographics of patients were not described. Outcomes were assessed 1 day after completion of a 3-week treatment period. Active PENS had better results on VAS pain, activity, sleep, and analgesic use than sham PENS. The authors described the study as investigator-blinded. No long-term outcome data were presented.

Subsection Summary: Diabetic Neuropathy
This single study does not permit conclusions on the effects of PENS for treating diabetic neuropathy.

Headache
Randomized Controlled Trials

Ahmed et al. (2000) conducted a crossover study in 30 patients with longstanding headaches of 3 types: tension, migraine, and posttraumatic injury.34 Two-week courses of active and sham PENS were compared. Outcomes were assessed at the completion of each treatment. Active PENS achieved better outcomes than sham PENS regarding VAS pain, physical activity, and quality of sleep. Results did not vary by headache type. The investigators stated that the study was single-blinded but gave no details about blinding methods or whether withdrawals occurred. The report did not offer long-term outcomes data.

Subsection Summary: Headache
This single study does not establish the effectiveness of PENS for treatment of a chronic headache.

Chronic Surface Hyperalgesia
Randomized Controlled Trials

Raphael et al. (2011) reported on a multicenter, double-blinded, randomized crossover trial of a single PENS treatment compared with a sham treatment in 30 patients with surface hyperalgesia due to a variety of chronic pain conditions.35 The pain diagnoses included surgical scar pain, occipital neuralgia, posttraumatic neuropathic pain, stump pain, inflammatory neuropathic pain, chronic low back pain, complex regional pain syndrome, pain following total knee arthroplasty, chronic cervical pain, and postherpetic neuralgia. The duration of pain ranged from 1 to 35 years (mean, 8.1 years). Subjective pain on a numeric rating scale (NRS) and a pressure pain threshold were measured before and 1 week after the single treatment, with a washout period of 4 weeks between treatments. Median NRS scores improved from 7.5 to 0.5 after active PENS and did not change after sham treatment (7.5 pre, 7.5 post). The mean pain pressure threshold improved from 202 to 626 grams after active PENS and did not change significantly after sham treatment (202 grams pre, 206 grams post). Blinding was maintained after the first treatment, but not after the second due to the tingling sensation with active PENS. Analysis of the first treatment showed a significant difference in NRS score change (3.9 vs 0.1) and the pain pressure threshold (310 g vs 8 g) for the active compared with sham treatment.

Subsection Summary: Chronic Surface Hyperalgesia
A single study has reported positive effects on PENS for chronic surface hyperalgesia. Longer term follow-up in a larger sample is needed to evaluate the efficacy and confirm clinically meaningful durability of this treatment approach.

Section Summary: Percutaneous Electrical Nerve Stimulation
A systematic review concluded that PENS could decrease the level of pain intensity, but not related disability, in musculoskeletal pain disorders. However, the overall level of evidence was low and there was heterogeneity with regard to application methods, leading to the conclusion that there is still high uncertainty regarding the effectiveness of PENS for musculoskeletal pain. The highest quality trial on PENS for chronic low back pain found no difference between the active (30 minutes with 10 needles) and sham PENS (5 minutes with 2 needles) at 1 week or 6 months posttreatment. While other smaller studies have suggested that active PENS has effects that exceed sham in the short term, none addressed long-term reductions in pain and improvements in functional outcomes, the objective of treating chronic pain. Most of the studies on PENS were reported by a single academic research group (including Ghoname, Hamza, Ahmed, and White) over a decade ago. A more recent study has reported positive effects on PENS for chronic surface hyperalgesia at 1 week after treatment. Longer term follow-up in a larger sample of patients is needed to evaluate the efficacy and confirm clinically meaningful durability of this treatment approach.

Percutaneous Neuromodulation Therapy
Clinical Context and Therapy Purpose

The purpose of percutaneous neuromodulation therapy (PNT) in patients who have pain is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does PNT improve the net health outcome in patients with chronic musculoskeletal or neuropathic pain conditions?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is patients with chronic musculoskeletal or neuropathic pain conditions including knee osteoarthritis.

Interventions
The therapy being considered is PNT.

Comparators
The following practice is currently being used: continued medical management of chronic musculoskeletal or neuropathic pain conditions.

Outcomes
Specific outcomes of interest for patients with chronic pain are listed in Table 1. The potential beneficial outcomes of primary interest would be improvements in pain, functioning, and quality of life.

The IMMPACT recommends that chronic pain trials should consider assessing outcomes representing 6 core domains: pain, physical functioning, emotional functioning, participant ratings of improvement and satisfaction with treatment, symptoms and adverse events, and participant disposition.2 Table 2 summarizes provisional benchmarks for interpreting changes in chronic pain clinical trial outcome measures per IMMPACT.3,

Regarding optimal timing of outcome assessment, this varies with pain setting.4, Per IMMPACT, recommended assessment timing includes at 3, 6, and 12 months in patients with chronic low back pain, 3 to 4 months after rash onset in postherpetic neuralgia, 3 and 6 months in patients with painful chemotherapy-induced peripheral neuropathy, and at various timepoints in the chronic post-surgical pain setting (i.e., 24 to 48 hours after surgery; 3, 6, and 12 months; or surgery-specific times based on the natural history of acute to chronic pain transition).

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

  • To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
  • In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
  • To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
  • Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Knee Osteoarthritis
Randomized Controlled Trials

Kang et al. (2007) reported on a single-blinded trial that included 70 patients with knee osteoarthritis randomized to stimulation (at the highest tolerable intensity) or placement of electrodes (without stimulation).36 Patients in the sham group were informed that they would not perceive the normal "pins and needles" with this new device. Patients received 1 treatment and were followed for 1 week. The neuromodulation group had 100% follow-up; 7 (20%) of 35 patients from the sham group dropped out. Visual analog scale pain scores improved immediately after active (from 5.4 to 3.2) but not sham (5.6 to 4.9) treatments. Visual analog scale scores did not differ significantly between the 2 groups at 48 hours posttreatment. Changes in the Western Ontario and McMaster Osteoarthritis Index scores were significantly better for stiffness (1-point change vs 0-point change) but not for pain or function at 48 hours.

Section Summary: Percutaneous Neuromodulation Therapy
One study was identified on PNT for osteoarthritis of the knee. Interpretation of this trial is limited by its lack of investigator blinding, 48-hour VAS pain scores, and a differential loss to follow-up in the 2 groups. These results raise questions about the effectiveness of the blinding, the contribution of short-term pain relief and placebo effects, and the duration of PNT treatment effects.

Summary of Evidence
For individuals who have chronic pain conditions (e.g., back, neck, neuropathy, headache, hyperalgesia) who receive PENS, the evidence includes primarily small controlled trials and 2 systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. Two systematic reviews have not revealed consistent benefit from PENS in musculoskeletal pain disorders. One review concluded that PENS could decrease pain intensity but not related disability, while the other found no significant differences between PENS and TENS in mitigation of pain. These conclusions are uncertain due to important methodological limitations in individual trials included in these reviews, such as high heterogeneity with regard to application methods. In the highest quality trial of PENS conducted to date in chronic low back pain, no difference in outcomes was found between the active (30 minutes of stimulation with 10 needles) and the sham (5 minutes of stimulation with 2 needles) treatments. Smaller trials, which have reported positive results, are limited by unclear blinding and short-term follow-up. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have chronic pain conditions (eg, knee osteoarthritis) who receive PNT, the evidence consists of an RCT. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. The single trial is limited by lack of investigator blinding, unclear participant blinding, and short-term follow-up. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2011 Input
In response to requests, input was received from 5 physician specialty societies and 2 academic medical centers while this policy was under review in 2011. Input was mixed on whether percutaneous electrical nerve stimulation (PENS) and percutaneous neuromodulation therapy should be considered investigational or medically necessary.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in Supplemental Information if they were issued by, or jointly by, a U.S. professional society, an international society with U.S. representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Institute for Health and Care Excellence
The National Institute for Health and Care Excellence (2013) published guidance on PENS.37 It concluded that the "Current evidence on the safety of [PENS] for refractory neuropathic pain raises no major safety concerns and there is evidence of efficacy in the short term."

American Academy of Neurology et al.
The American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation reaffirmed 2011 evidence-based guidelines on the treatment of painful diabetic neuropathy in 2016.38 The guidelines concluded that, based on a class I study, electrical stimulation is probably effective in lessening the pain of diabetic neuropathy and improving quality of life and recommended that PENS be considered for the treatment of painful diabetic neuropathy (level B). The guidelines were retired and replaced in 2022 with a guideline dedicated to oral and topical treatment of painful diabetic polyneuropathy.39 In these updated guidelines, there is no mention of any electrical stimulation strategies for pain.

American Society of Anesthesiologists et al.
The 2010 practice guidelines for chronic pain management from the American Society of Anesthesiologists and the American Society of Regional Anesthesia and Pain Medicine indicated that subcutaneous peripheral nerve stimulation might be used in the multimodal treatment of patients with painful peripheral nerve injuries who have not responded to other therapies (category B2 evidence, observational studies).40

American College of Physicians and American Pain Society
Joint practice guidelines on the diagnosis and treatment of low back pain from the American College of Physicians and the American Pain Society in 2007 indicated uncertainty over whether PENS should be considered a novel therapy or a form of electroacupuncture.41 The guidelines concluded that PENS is not widely available. The guidelines also concluded that transcutaneous electrical nerve stimulation has not been proven effective for chronic low back pain. These guidelines were updated in 2017 and authors stated that evidence was insufficient to determine harms associated with PENS thus, no recommendation was made.42

U.S. Preventive Services Task Force Recommendations
Not applicable

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 6.

Table 6. Summary of Key Trials

NCT No. Trial Name Planned Enrollment Completion Date
Ongoing      
NCT04243915 Effectiveness of Percutaneous Neuromuscular Electrical Stimulation on Lumbar Multifidus in Combination With a Protocol of Motor Control Exercises in Patients With Chronic Low Back Pain 64 Apr 2021
NCT04454671 Efficacy of Ultrasound-guided Percutaneous Neuromodulation Versus Ultrasound-guided Dry Needling of the Supravascular Nerve in Shoulder Pain 62 Nov 2022
NCT04442321 Effectiveness of Ultrasound-Guided Percutaneous Electrical Stimulation on Radial Nerve With Exercises in Patients With Lateral Epicondylalgia 60 June 2022
Unpublished      
NCT03331055 Percutaneous Electrical Nerve Stimulation or Transcutaneous Electrical Nerve Stimulation for Pain in Patients With Pancreatic Cancer 36 Aug 2019
NCT03338543 Percutaneous Electrical Nerve Stimulation or Transcutaneous Electrical Nerve Stimulation for Pain in Patients With Liver Cancer 36 Aug 2019

NCT: national clinical trial.

References 
  1. Centers for Disease Control and Prevention (CDC). By the Numbers: Diabetes in America. Updated March 2022; https://www.cdc.gov/diabetes/health-equity/diabetes-by-the-numbers.html. Accessed May 5, 2022.
  2. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. Jan 2005; 113(1-2): 9-19. PMID 15621359
  3. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. Feb 2008; 9(2): 105-21. PMID 18055266
  4. Gewandter JS, Dworkin RH, Turk DC, et al. Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain. Jul 2015; 156(7): 1184-1197. PMID 25887465
  5. Plaza-Manzano G, Gomez-Chiguano GF, Cleland JA, et al. Effectiveness of percutaneous electrical nerve stimulation for musculoskeletal pain: A systematic review and meta-analysis. Eur J Pain. Jul 2020; 24(6): 1023-1044. PMID 32171035
  6. Beltran-Alacreu H, Serrano-Munoz D, Martin-Caro D, et al. Percutaneous versus transcutaneous electrical nerve stimulation for the treatment of musculoskeletal pain. A systematic review and meta-analysis. Pain Med. Feb 15 2022. PMID 35167691
  7. Ghoname EA, Craig WF, White PF, et al. Percutaneous electrical nerve stimulation for low back pain: a randomized crossover study. JAMA. Mar 03 1999; 281(9): 818-23. PMID 10071003
  8. Ghoname ES, Craig WF, White PF, et al. The effect of stimulus frequency on the analgesic response to percutaneous electrical nerve stimulation in patients with chronic low back pain. Anesth Analg. Apr 1999; 88(4): 841-6. PMID 10195535
  9. Hamza MA, Ghoname EA, White PF, et al. Effect of the duration of electrical stimulation on the analgesic response in patients with low back pain. Anesthesiology. Dec 1999; 91(6): 1622-7. PMID 10598602
  10. Weiner DK, Rudy TE, Glick RM, et al. Efficacy of percutaneous electrical nerve stimulation for the treatment of chronic low back pain in older adults. J Am Geriatr Soc. May 2003; 51(5): 599-608. PMID 12752833
  11. Topuz O, Ozfidan E, Ozgen M, Ardic F. Efficacy of transcutaneous electrical nerve stimulation and percutaneous neuromodulation therapy in chronic low back pain. J Back Musculoskeletal Rehabil. 2004;17:127-133.
  12. Yokoyama M, Sun X, Oku S, et al. Comparison of percutaneous electrical nerve stimulation with transcutaneous electrical nerve stimulation for long-term pain relief in patients with chronic low back pain. Anesth Analg. Jun 2004; 98(6): 1552-1556. PMID 15155304
  13. Weiner DK, Perera S, Rudy TE, et al. Efficacy of percutaneous electrical nerve stimulation and therapeutic exercise for older adults with chronic low back pain: a randomized controlled trial. Pain. Nov 30 2008; 140(2): 344-357. PMID 18930352
  14. Perez-Palomares S, Olivan-Blazquez B, Magallon-Botaya, et al. Percutaneous electrical nerve stimulation versus dry needling: effectiveness in the treatment of chronic low back pain. J Musculokeletal Pain. 2010;18:23-30.
  15. Weiner DK, Rudy TE, Morone N, et al. Efficacy of periosteal stimulation therapy for the treatment of osteoarthritis-associated chronic knee pain: an initial controlled clinical trial. J Am Geriatr Soc. Oct 2007; 55(10): 1541-7. PMID 17908057
  16. Weiner DK, Moore CG, Morone NE, et al. Efficacy of periosteal stimulation for chronic pain associated with advanced knee osteoarthritis: a randomized, controlled clinical trial. Clin Ther. Nov 2013; 35(11): 1703-20.e5. PMID 24184053
  17. da Graca-Tarrago M, Deitos A, Patricia Brietzke A, et al. Electrical Intramuscular Stimulation in Osteoarthritis Enhances the Inhibitory Systems in Pain Processing at Cortical and Cortical Spinal System. Pain Med. May 01 2016; 17(5): 877-891. PMID 26398594
  18. Elbadawy MA. Effectiveness of Periosteal Stimulation Therapy and Home Exercise Program in the Rehabilitation of Patients With Advanced Knee Osteoarthritis. Clin J Pain. Mar 2017; 33(3): 254-263. PMID 27513639
  19. Dunning J, Butts R, Henry N, et al. Electrical dry needling as an adjunct to exercise, manual therapy and ultrasound for plantar fasciitis: A multi-center randomized clinical trial. PLoS One. 2018; 13(10): e0205405. PMID 30379937
  20. da Graca-Tarrago M, Lech M, Angoleri LDM, et al. Intramuscular electrical stimulus potentiates motor cortex modulation effects on pain and descending inhibitory systems in knee osteoarthritis: a randomized, factorial, sham-controlled study. J Pain Res. 2019; 12: 209-221. PMID 30655690
  21. Leon-Hernandez JV, Martin-Pintado-Zugasti A, Frutos LG, et al. Immediate and short-term effects of the combination of dry needling and percutaneous TENS on post-needling soreness in patients with chronic myofascial neck pain. Braz J Phys Ther. Jul 11 2016; 20(5): 422-431. PMID 27410163
  22. Sumen A, Sarsan A, Alkan H, et al. Efficacy of low level laser therapy and intramuscular electrical stimulation on myofascial pain syndrome. J Back Musculoskelet Rehabil. 2015; 28(1): 153-8. PMID 25061034
  23. Medeiros LF, Caumo W, Dussan-Sarria J, et al. Effect of Deep Intramuscular Stimulation and Transcranial Magnetic Stimulation on Neurophysiological Biomarkers in Chronic Myofascial Pain Syndrome. Pain Med. Jan 2016; 17(1): 122-35. PMID 26408420
  24. Botelho L, Angoleri L, Zortea M, et al. Insights About the Neuroplasticity State on the Effect of Intramuscular Electrical Stimulation in Pain and Disability Associated With Chronic Myofascial Pain Syndrome (MPS): A Double-Blind, Randomized, Sham-Controlled Trial. Front Hum Neurosci. 2018; 12: 388. PMID 30459575
  25. Dunning J, Butts R, Young I, et al. Periosteal Electrical Dry Needling as an Adjunct to Exercise and Manual Therapy for Knee Osteoarthritis: A Multicenter Randomized Clinical Trial. Clin J Pain. Dec 2018; 34(12): 1149-1158. PMID 29864043
  26. Yoshimizu M, Teo AR, Ando M, Kiyohara K, Kawamura T. Relief of chronic shoulder and neck pain by electro-acupuncture and transcutaneous electrical nervous stimulation: A randomized crossover trial. Med Acupunct 2012;24(2):97103.
  27. Ng MM, Leung MC, Poon DM. The effects of electro-acupuncture and transcutaneous electrical nerve stimulation on patients with painful osteoarthritic knees: a randomized controlled trial with follow-up evaluation. J Altern Complement Med. Oct 2003; 9(5): 641-9. PMID 14629842
  28. Tsukayama H, Yamashita H, Amagai H, et al. Randomised controlled trial comparing the effectiveness of electroacupuncture and TENS for low back pain: a preliminary study for a pragmatic trial. Acupunct Med. Dec 2002; 20(4): 175-80. PMID 12512791
  29. Cheng RSS, Pomeranz B. Electrotheraphy of chronic musculoskeletal pain: Comparison of electroacupuncture and acupuncture-like transcutaneous electrical nerve stimulation. Cochrane Library. Clin J Pain 1986;2(3):1439.
  30. Lehmann TR, Russell DW, Spratt KF, et al. Efficacy of electroacupuncture and TENS in the rehabilitation of chronic low back pain patients. Pain. Sep 1986; 26(3): 277-290. PMID 2946016
  31. Ghoname EA, White PF, Ahmed HE, et al. Percutaneous electrical nerve stimulation: an alternative to TENS in the management of sciatica. Pain. Nov 1999; 83(2): 193-9. PMID 10534590
  32. White PF, Craig WF, Vakharia AS, et al. Percutaneous neuromodulation therapy: does the location of electrical stimulation effect the acute analgesic response?. Anesth Analg. Oct 2000; 91(4): 949-54. PMID 11004055
  33. Hamza MA, White PF, Craig WF, et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. Diabetes Care. Mar 2000; 23(3): 365-70. PMID 10868867
  34. Ahmed HE, White PF, Craig WF, et al. Use of percutaneous electrical nerve stimulation (PENS) in the short-term management of headache. Headache. Apr 2000; 40(4): 311-5. PMID 10759936
  35. Raphael JH, Raheem TA, Southall JL, et al. Randomized double-blind sham-controlled crossover study of short-term effect of percutaneous electrical nerve stimulation in neuropathic pain. Pain Med. Oct 2011; 12(10): 1515-22. PMID 21883874
  36. Kang RW, Lewis PB, Kramer A, et al. Prospective randomized single-blinded controlled clinical trial of percutaneous neuromodulation pain therapy device versus sham for the osteoarthritic knee: a pilot study. Orthopedics. Jun 2007; 30(6): 439-45. PMID 17598487
  37. National Institute for Health and Care Excellence (NICE). Percutaneous electrical nerve stimulation for refractory neuropathic pain [IPG450]. 2013; https://www.nice.org.uk/guidance/ipg450. Accessed May 5, 2022.
  38. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. May 17 2011; 76(20): 1758-65. PMID 21482920
  39. Price R, Smith D, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee. Neurology. Jan 04 2022; 98(1): 31-43. PMID 34965987
  40. Benzon HT, Connis RT, De Leon-Casasola OA, et al. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. Apr 2010; 112(4): 810-33. PMID 20124882
  41. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. Oct 02 2007; 147(7): 478-91. PMID 17909209
  42. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. Apr 04 2017; 166(7): 514-530. PMID 28192789
  43. Centers for Medicare & Medicaid. National Coverage Determination (NCD) for Assessing Patient's Suitability for ELECTRICAL NERVE STIMULATION Therapy (160.7.1). 2006; https://www.cms.gov/medicare-coverage- database/details/ncd- details.aspx?NCDId = 63&ncdver = 2&CoverageSelection = National&KeyWord = Electrical+Nerve+Stimulation&Key WordLookUp = Title&KeyWordSearchType = And&list_type = ncd&bc = gAAAABAAAAAA&. Accessed May 5, 2022.

Coding Section

Codes Number Description
CPT 64999

Unlisted procedure, nervous system

ICD-9 Procedure 86.09

Other incision of skin and subcutaneous tissue

ICD-9 Diagnosis  

See “Pain” in ICD-9-Diagnosis index

HCPCS No specific codes  
ICD-10-CM (effective 10/01/15)  

Investigational for all diagnoses.

 

G56.40-G56.42

Causalgia of upper limb code range

 

G57.70-G57.72

Causalgia of lower limb code range

 

G89.21-G89.8

Chronic pain, not elsewhere classified, code range

 

G89.4

Chronic pain syndrome

 

G90.50-G90.59

Complex regional pain syndrome I (CRPS I), code range

 

M25.50- M25.579

Pain in joint, code range

 

M54.10- M54.18

Radiculopathy, code range

 

M54.30-M54.32

Sciatica, code range

 

M54.40-M54.42

Lumbago with sciatica, code range 

 

M54.5

Low back pain 

 

M54.6

Pain in thoracic spine 

 

M54.81, M54.89

Other dorsalgia codes

 

M54.9

Dorsalgia, unspecified 

 

M79.1

Myalgia 

 

M79.60-M79.6

Pain in limb, hand, foot, fingers and toes code range 

 

R52

Pain, unspecified

ICD-10-PCS (effective 10/01/15)   

ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for this therapy. 

 

01HY3MZ 

Surgical, peripheral nervous system, insertion, peripheral nerve, percutaneous, neurostimulator lead

Type of Service  Surgery   
Place of Service   Inpatient/Outpatient  

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive. 

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross Blue Shield Association technology assessment program (TEC) and other nonaffiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2014 Forward     

08/16/2023 Annual review, no change to policy intent.
08/17/2022 Annual review, no change to policy intent. Updating rationale and references.

08/03/2021 

Annual review, no change to policy intent. Updating rationale and references. 

08/03/2020 

Annual review, no change to policy intent. Updating rationale and references. 

08/01/2019 

Annual review, no change to policy intent. 

08/09/2018 

Annual review, no change to policy intent. Updating background, rationale and references. 

08/24/2017 

Annual review, no change to policy intent, but, policy verbiage has been expanded for clarity. Also updating background, description, regulatory status, rationale and references. 

08/02/2016 

Annual review, no change to policy intent. 

08/13/2015 

Annual review, no change to policy intent. Updated background, description, rationale and references. Added guidelines and coding. 

07/29/2014

Annual review. Added related policies. Updated rationale and references. No change to policy intent.

Complementary Content
${loading}